---
title: "Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302909326.md"
datetime: "2026-10-23T16:24:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302909326.md)
  - [en](https://longbridge.com/en/news/302909326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302909326.md)
generator: "portal-rs"
---

# Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause

Oct 23 (Reuters) - Bristol-Myers Squibb Spokesperson>:

-   BRISTOL-MYERS SPOKESPERSON: GRADE 5 EVENT THAT WAS DISCLOSED AS PART OF DATA DISCLOSURE AT MS TORONTO OCCURRED AFTER TRIAL PAUSE
-   BRISTOL-MYERS SQUIBB SPOKESPERSON: WORKING CLOSELY WITH FDA TO RESTART TRIAL AS SOON AS POSSIBLE, WITH THE GOAL OF RESUMING ENROLLMENT IN EARLY 2027
-   BRISTOL-MYERS SPOKESPERSON: GRADE 5 EVENT THAT WAS DISCLOSED WAS NOT RELATED TO OUR DECISION TO PAUSE THE BREAKFREE PROGRAM

Source text:

Further company coverage: (BMY.N)

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%](https://longbridge.com/en/news/301304214.md)
- [Crypto Strategist Who Nailed 2025 Bitcoin Top Warns BTC Could Drop Below $70,000 – Here’s His Price Target](https://longbridge.com/en/news/302980144.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**